• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Med Clin North Am . Antivirals Improve Outcomes in Influenza

tetano

Editor, Senior Moderator
Emerg Med Clin North Am


. 2026 Aug;44(3):495-505.
doi: 10.1016/j.emc.2026.01.005. Epub 2026 May 7.
Antivirals Improve Outcomes in Influenza

Tonmoy Shanto[SUP] 1 [/SUP], Yusuf Zarhiya[SUP] 1 [/SUP], Jaclyn Dibello[SUP] 1 [/SUP], Abbas Husain[SUP] 2 [/SUP]


Affiliations
Abstract

Influenza is a significant global health concern, with millions of cases, hospitalizations, and deaths annually, particularly impacting older adults and children. Antivirals like neuramidase inhibitors (oseltamivir, zanamivir, and peramivir) and endonuclease inhibitors (baloxavir) can help with treatment when started within 48 hours of symptom onset, primarily shortening illness duration by about 1 day. They should also be considered for treatment of hospitalized, severely ill, or high-risk patients (ie. elerly, pregnant and immunocompromized). However, for healthy, low-risk outpatients, the clinical benefit is modest, adn the risk of side effects is high.

Keywords: Antiviral; Influenza; Neuraminidase; Oseltamivir; Peramivir; Zanamivir.

 
Back
Top